Specifically, BTK is a tissue specific target for inhibition in various B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) (Davis et al., 2010; Herishanu et al., 2011); proliferation of these lymphomas strictly depends on the activation of the BTK signaling cascade. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.